<DOC>
	<DOCNO>NCT02796131</DOCNO>
	<brief_summary>A Phase 1 , single-center , randomize , double-blind , placebo-controlled study evaluate safety , tolerabiltiy , pharmacodynamics different multiple dose regimen RDX5791 healthy volunteer .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacodynamics RDX5791 Healthy Volunteers</brief_title>
	<detailed_description>The starting dose study base result multiple ascending-dose study perform RDX5791 ( Protocol RDX5791-101 ) . Subjects screen within 3 week check CPU . Each cohort 15 subject ( 12 RDX5791 , 3 placebo ) check CPU Day -5 dinner . Each subject receive diet standardized Na+ content CPU . Subjects receive dos RDX5791 approximately 240 mL non-carbonated water Days 1 7 ( prior meal , depend QD , bid , tid regimen ) . Subjects provide standardized meal within 10 minute dose . Doses administer breakfast , lunch , dinner .</detailed_description>
	<mesh_term>Psyllium</mesh_term>
	<criteria>Body mass index 18 29.9 kg/m² , inclusive No clinically significant abnormality medical history Females must nonpregnant , nonlactating , either postmenopausal least 12 month agree use effective form contraception time sign informed consent 45 day end study Men must either sterile , abstinent , agree use approve method contraception checkin 45 day final study visit Diagnosis treatment clinically symptomatic biochemical structural abnormality GI tract Any surgery small intestine colon , exclude appendectomy Loose stool ( Bristol Stool Form Score 6 7 ) ≥2 day past 7 day Hepatic dysfunction ( [ ALT ] [ AST ] ) &gt; 1.5 time upper limit normal renal impairment Any evidence treatment malignancy , exclude nonmelanomatous malignancy skin Use diuretic medication , medication know affect stool consistency and/or GI motility Use investigational agent within 30 day prior Day 2 Positive virology , alcohol , drug abuse test screening Use prescription medication within 7 day admission CPU Have significant blood loss ( &gt; 450 mL ) donate 1 unit blood plasma within 8 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Healthy</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>